基于“脾主为卫”探讨氨基酸在代谢功能障碍相关脂肪性肝病中的干预机制及临床应用Exploration of the intervention mechanisms and clinical applications of amino acids in metabolic dysfunction-associated steatotic liver disease based on the theory of "spleen governing defense"
孙菁,杨宇峰,刘元君,田列
摘要(Abstract):
代谢功能障碍相关脂肪性肝病(metabolic dysfunction-associated steatotic liver disease, MASLD)是一类以肝细胞脂肪变性为特征,并伴有至少一项心脏代谢风险因素,且排除过量饮酒及其他明确肝损伤病因的慢性进展性肝脏疾病。研究表明,氨基酸与MASLD的发生有密切联系,氨基酸及其代谢产物影响MASLD的发生、发展,“脾主为卫”功能在MASLD的治疗中起着重要作用,然而其潜在的作用机制尚不清楚。“脾主为卫”与氨基酸有着相似的学术内涵,从氨基酸的角度出发,分析中医“脾主为卫”理论并作出新的科学解读,得出MASLD患者出现氨基酸紊乱与氨基酸代谢异常及炎症反应等有关,为MASLD的治疗提供新的理论支撑及治疗方案。
关键词(KeyWords): 代谢功能障碍相关脂肪性肝病;脾主为卫;氨基酸;临床应用
基金项目(Foundation): 苏州市“科教兴卫”青年科技项目(No:KJXW2023049);; 苏州市第一批中青年中医临床优秀人才研修项目(No:苏卫健中医便函〈2023〉43号);; 辽宁省科技计划项目——应用基础研究计划项目(No:2025JH2/101330106)
作者(Author): 孙菁,杨宇峰,刘元君,田列
参考文献(References):
- [1] Younossi ZM,Golabi P,Paik JM,et al.The global epidemiology of nonalcoholic fatty liver disease(NAFLD) and nonalcoholic steatohepatitis(NASH):a systematic review[J].Hepatology,2023,77(4):1335-1347.
- [2] Kuchay MS,Choudhary NS,Ramos-Molina B.Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease[J].Am J Physiol Cell Physiol,2025,328(5):C1637-C1666.
- [3] 朱博文,王星云,郭锡熔.氨基酸调控糖脂代谢在脂肪肝形成中的作用[J].中国儿童保健杂志,2025,33(10):1070-1073.
- [4] 李蕊,沈文清.猪去氧胆酸通过肠-肝轴治疗MASLD的机制研究进展[J].生理学报,2026,78(3):536-550.
- [5] Sun DY,Xie CP,Zhao Y,et al.The gut microbiota-bile acid axis in cholestatic liver disease[J].Mol Med,2024,30(1):104.
- [6] 黄帝内经[M].姚春鹏,译注.北京:中华书局,2022.
- [7] 李东垣.脾胃论[M].文魁,丁国华,整理.北京:人民卫生出版社,2023.
- [8] 范建高,徐小元,南月敏,等.代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J].实用肝脏病杂志,2024,27(4):494-510.
- [9] 姜婷,纪文岩,陆为民.从肠道菌群浅析“脾为之卫”的科学内涵与临床应用[J].中国中西医结合杂志,2020,40(10):1268-1272.
- [10] 刘瑞源,梁舒渝,杨俊威,等.基于脾主为卫探讨肠道菌群在帕金森病治疗中的干预机制及临床应用[J].中医临床研究,2026,18(7):98-104.
- [11] Huang T,Song J,Gao J,et al.Adipocyte-derived kynurenine promotes obesity and insulin resistance by activating the AhR/STAT3/IL-6 signaling[J].Nat Commun,2022,13(1):3489.
- [12] Hu XM,Guo FF.Amino acid sensing in metabolic homeostasis and health[J].Endocr Rev,2021,42(1):56-76.
- [13] Liao YL,Chen QS,Liu L,et al.Amino acid is a major carbon source for hepatic lipogenesis[J].Cell Metab,2024,36(11):2437-2448.e8.
- [14] Li SY,Ogawa W,Emi A,et al.Role of S6K1 in regulation of SREBP1c expression in the liver[J].Biochem Biophys Res Commun,2011,412(2):197-202.
- [15] Lefebvre R,Rousseaux T,Bendridi N,et al.N-acetyl-phenylalanine induces hepatic steatosis in MASLD by disrupting ER-mitochondria calcium coupling and mitochondrial lipid oxidation[J].BioRxiv,2025:2025.09.24.678188.
- [16] Wipfli F,Lone MA,von Eckardstein A,et al.Increased 1-deoxysphingolipids caused by an altered plasma alanine to serine ratio are associated with metabolic dysfunction-associated steatotic liver disease(MASLD)[J].Metabolomics,2025,21(6):157.
- [17] Chen Y,Wang YR,Shen TJ,et al.Serum metabolic signatures and MetalnFF diagnostic score for mild and moderate metabolic dysfunction-associated steatotic liver disease[J].J Pharm Biomed Anal,2025,260:116772.
- [18] Zamosteanu D,Filip N,Lozneanu L,et al.Amino acids:potential biomarkers of histological features for MASLD in pediatric obesity[J].Int J Mol Sci,2026,27(8):3596.
- [19] Trillos-Almanza MC,Aguilar MM,Buist-Homan M,et al.Branched-chain amino acids and their metabolites decrease human and rat hepatic stellate cell activation[J].Mol Biol Rep,2024,51(1):1116.
- [20] Mino M,Kakazu E,Sano A,et al.Comprehensive analysis of peripheral blood free amino acids in MASLD:the impact of Glycine-serine-threonine metabolism[J].Amino Acids,2024,57(1):3.
- [21] Steinberg GR,Valvano CM,De Nardo W,et al.Integrative metabolism in MASLD and MASH:Pathophysiology and emerging mechanisms[J].J Hepatol,2025,83(2):584-595.
- [22] Luo X,Wang K,Jiang CT.Gut microbial enzymes and metabolic dysfunction-associated steatohepatitis:Function,mechanism,and therapeutic prospects[J].Cell Host Microbe,2025,33(6):836-853.
- [23] Wang ZJ,Wang YN,Zhang J,et al.Multi-omics approaches to explore the therapeutic mechanism for ginsenoside Rg1 against MASLD[J].Biochem Biophys Res Commun,2025,776:152161.
- [24] Jing MH,Jiang YY.Microbiome-mediated crosstalk between T2DM and MASLD:a translational review focused on function[J].Front Endocrinol,2025,16:1677175.
- [25] 张荣,徐强,窦婧,等.基于肠道菌群探讨中医从脾胃论治代谢相关脂肪性肝病的理论基础[J].云南中医药大学学报,2024,47(5):1-5.
- [26] 岑璐,韩宇博,姚春丽,等.基于肠道菌群-炎症反应的中医药干预代谢综合征的研究进展[J].中国医药导报,2025,22(5):52-56.
- [27] 曾孟颜,姚嘉欣,张茜,等.基于网络药理学探讨四君子汤治疗非酒精性脂肪性肝病的作用机制[J].中医临床研究,2022,14(16):1-8.
- [28] 丁俊瑶,黄萍,陈智炜,等.四君子汤合三子养亲汤治疗小鼠代谢相关脂肪性肝病作用和机制研究[J].新中医,2025,57(16):190-199.
- [29] 唐凯锐.参苓白术散对NAFLD大鼠肝细胞TLR4/MyD88信号通路的影响[C]//中国中西医结合学会.2017年第五次世界中西医结合大会论文摘要集(上册).2017:460-460.
- [30] 赖靖江,禚孝丽,蒋凤仙,等.参苓白术散在多种疾病模型中的潜在作用机制[J].中国实验方剂学杂志,2022,28(20):267-273.
- [31] 税嘉诚,胡财愿,刘奕均,等.参苓白术散的实验研究进展[J].医学信息,2014,27(30):335-336.
- [32] Markova M,Pivovarova O,Hornemann S,et al.Isocaloric diets high in animal or plant protein reduce liver fat and inflammation in individuals with type 2 diabetes[J].Gastroenterology,2017,152(3):571-585.e8.
- [33] Fang YC,Fang ZY,Li ZW,et al.The role of the gut-liver axis in modulating non-alcoholic fatty liver disease through dietary patterns and microecological agents[J].Food Bioscience,2023,56(6):269-283.
- [34] Ikenaga H,Fujii H,Uchida-Kobayashi S.From dietary patterns to metabolic phenotypes in MASLD:promise and caution[J].Hepatol Int,2026,20(4):992-994.
- [35] Williams GM,Hoedt EC,Duncanson K,et al.Inverse associations between Mediterranean diet constituents and the gut microbiota in metabolic-associated steatotic liver disease(MASLD):a case-control study[J].Nutr Metab,2025,23(1):8.